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DNA immunization in conjunction with antiretroviral therapy was evaluated in SIV-infected rhesus macaques treated with [R]-9-[2-
phosphonylmethoxypropyl]adenine (PMPA). Macaques were immunized monthly with DNA vaccines expressing either SIV gag/tat or SIV gag/
tat and 19 CD8+ T cell epitopes during 7 months of therapy. Half the animals from each group were additionally immunized before infection.
Only 60% of the animals (4 controls, 20 vaccinated) responded to PMPA (ART responders). All 4 ART responder controls demonstrated viral
rebound or CD4 decline after PMPAwas withdrawn. In contrast, 17 of 20 vaccinated ART responders contained viral rebound for over 7 months
after PMPA was withdrawn. Viral control correlated with stable CD4 counts, higher lymphoproliferation and an increase in the magnitude and
breadth of the CD8+ T cell response. Immunizing before infection or with multi-epitopes enhanced these effects. These results demonstrate that
DNA immunization during antiretroviral therapy may be an effective strategy to treat HIV infection.
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Despite considerable progress, an effective vaccine against
HIV is not yet available, and clinical management of AIDS
currently depends on long-term treatment with a cocktail of
antiretroviral drugs (highly active antiretroviral therapy;
HAART). Although HAART has proven to be effective in
decreasing symptoms and prolonging life in patients infected
with HIV-1 (UNAIDS, 2000), the long-term benefits are limited
by the emergence of drug resistant strains (Pillay et al., 2000),
complex dosing schedules, toxicity (Carr et al., 1998; Vigour-
oux et al., 1999), and the failure to deplete viral reservoirs
(Chun et al., 1997; de Jong et al., 1997; Staszewski et al.,
1998).
Table 1
Conservation between SIVmac239 CTL epitopes in the gag/tat/multi-epitope
DNA vaccine and the heterologous primary isolate SIV/DeltaB670 or similar
H9 consensus sequence as indicated
CTL epitopes in
multi-epitope DNA
vaccine
Sequence Conservation of
epitopes a
Gag_CM9 CTPYDINQM Y→ S (H9)
Tat_SL8 b STPESANL 1st S→ D, N→ S
Env_SI9 SWPWQIEYI 100%
Vif_QA9 QVPSLQYLA 100%
Pol_LV10 LGPHYTPKIV H→ N (H9)
Env_ST10 SPPSYFQTHT Highly variable
Env_CL9 CAPPGYALL 100%
Pol_YI9 YTPKIVGGI 100%
Pol_EA11 EAPQFPHGSSA SSA→ SDA (H9)
Gag_VT10 VNPTLEEMLT V→ M (H9)
Pol_SV9 STPPLVRLV 100%
Pol_QF10 QMPRQTGGFF Highly variable
Vif_VI8 VTPDYADI I→ T
Tat_TL8* TTPESANL 1st T→ D, N→ S
Pol_IL10 IYPGIKTKHL 100%
Env_TL9 TVPWPNASL AS→ DT
Pol_MI8 MTPAERLI I→ V
Pol_QV9 QVPKFHLPV K→ R
Gag_LA9 LAPVPIPFA Highly variable
Pol_GM10 GSPAIFQYTM Y→ H
a → indicates the amino acid differences between CTL epitopes included in
the vaccine and SIV/DeltaB670 or H9 consensus sequences.
b Since recognition of Tat_SL8 and Tat_TL8 by PBMC from infected
macaques is indistinguishable, they are considered the same epitope.
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infection have focused on immunotherapeutic intervention as
an adjunct to HAART. HAART reduces plasma viremia and
partially restores immune function in HIV-infected patients
(Autran et al., 1997, 1999; Emery and Lane, 1997; Valdez et
al., 2000). Immune restoration during HAART is characterized
by a rise in CD4+ T cell counts (Autran et al., 1997, 1999;
Emery and Lane, 1997), reconstitution of antibody and T cell
responses to recall antigens (Kim et al., 2001; Valdez et al.,
2000), and partial restoration of HIV-specific antibody
responses (Kim et al., 2001). HIV-specific CTL and CD4+ T
helper cells play a critical role in controlling HIV replication
and determining viral set point (16–18, 20, 21, 24, 27). How-
ever, depletion and/or anergy of HIV-specific CD4+ T cells,
which are required to sustain CD8+ T cell antiviral activity
(Janssen et al., 2003; Matloubian et al., 1994; Shedlock and
Shen, 2003; Sun and Bevan, 2003; Zajac et al., 1998), occurs
during the earliest stages of infection (Douek et al., 2003) and
HAART is unable (Casazza et al., 2001; Ghanekar et al., 2001;
Kalams et al., 1999; Valdez, 2002) or under certain conditions,
provides only partial restoration of these responses (Lopez et
al., 2004). These findings suggest that improving HIV-specific
T cell responses during HAART by immunotherapeutic inter-
vention may be an effective strategy to improve treatment of
HIV infection. In particular, immunizing infected patients with
vaccines that boost HIV-specific CTL and T helper cell
responses after HAART has reduced the virus burden may
restore these responses to levels that can better control HIV
during HAART or even in the absence of HAART.
DNA vaccines induce virus-specific CD4+ and CD8+ T cell
responses (Donnelly et al., 1997), and have been extensively
studied in the rhesus macaque model for AIDS. Challenge
studies have shown that DNA vaccines administered either
alone or in combination with recombinant viral vaccines can
provide complete or partial protection against avirulent and
homologous, pathogenic AIDS viruses (Amara et al., 2001;
Barouch et al., 2000; Boyer et al., 1997; Kent et al., 1998;
Robinson et al., 1999). In addition, we have previously shown
that delivery of DNA vaccines directly into the cells of the skin
using a particle mediated delivery device or gene gun can also
provide significant protection against challenge with a primary,
heterologous SIV isolate (Fuller et al., 2002). Since effective
treatment of an established HIV infection will need to target
diverse viral variants, this result suggests that DNA vaccination
may be a promising approach for immunotherapy as well. Here,
we investigated two DNAvaccines in rhesus macaques infected
with a heterologous primary isolate of SIV for their ability to
augment virus-specific T cell responses and control viremia
after discontinuation of monotherapy with the nucleoside in-
hibitor, [R]-9-[2-phosphonylmethoxypropyl]adenine (PMPA).
Results
Study design
An effective immunotherapeutic vaccine will likely need to
induce multiple specific CTL responses to enable targeting ofdiverse viral isolates. We constructed an epitope-based DNA
vaccine encoding 19 Mamu-A*01-restricted SIVmac239-specific
CTL epitopes using an approach wherein the epitope sequences
are inserted into the gene encoding hepatitis B core antigen to
enhance epitope immunogenicity (Lesinski et al., 2001). The
epitopes were selected by their ability to bind the Mamu-A*01
MHC class I molecule and be recognized in SIV-infected
macaques (Table 1) (Allen et al., 2001). The HBc-epitope
vaccine was combined with whole gene DNA vaccines encod-
ing SIVmac239 gag and tat to provide SIV-specific T cell help
(gag/tat/multi-epitope vaccine). This vaccine and separately,
the gag/tat DNA vaccine alone (gag/tat vaccine) were evaluat-
ed for immunogenicity and therapeutic efficacy in the SIV
rhesus macaque model for AIDS. Both DNA vaccines were
administered using particle-mediated epidermal delivery
(PMED), a method that has been previously shown to be highly
effective for inducing immune responses in both nonhuman
primates (Fuller et al., 1997a, 2002; Kent et al., 1998) and
humans (McConkey et al., 2003; Roberts et al., 2005; Rottin-
ghaus et al., 2003; Roy et al., 2000).
Sixteen animals were immunized both before and after in-
fection to test the effects of vaccine-priming on post-infection
immunotherapy (Fig. 1, Groups A and B). A second group of
sixteen animals were immunized only post-infection during
ART to test the effect of immunizing after infection was estab-
lished (Fig. 1, Groups C and D). Eight animals in each group
were immunized with the gag/tat/multi-epitope DNA vaccine
(Groups A and C), and the remaining 8 received the gag/tat
vaccine (Groups B and D). Mamu-A*01-positive monkeys
Fig. 1. Study design. Arrows indicate each DNA immunization. Each dose consisted of 32 μg of DNA of either the SIV gag/tat/multi-epitope or gag/tatDNAvaccine.
Animals were inoculated intravenously with 10 TCID50 of SIV/DeltaB670. Antiretroviral therapy (ART) consisted of 20 mg/kg/day of the nucleophosphonate analog
R-9-(2-phosphonylmethoxypropyl) adenine (PMPA) and was administered without interruption during weeks 2–30 post-infection. PMPAwas withdrawn at week 30
to assess the effects of vaccination on viral control. Vaccine efficacy was evaluated at 6 and 12 months post-PMPA.
202 D.H. Fuller et al. / Virology 348 (2006) 200–215were used for testing the gag/tat/multi-epitope vaccine because
expression of this molecule is required for recognition of the
epitopes and Mamu-A*01-negative monkeys were used to test
the gag/tat vaccine. To control for possible influences of the
Mamu-A*01 allele, the ART-treated control group consisted of
4 Mamu-A*01-positive and 4 Mamu-A*01-negative animals
(Group E). Mock vaccinations in this group consisted of immu-
nizations before and after infection with the empty HBcAg
carrier vector.
Pre-infection immune responses in vaccine-primed animals
Vaccine-primed animals received 4 DNA immunizations at
6–8 week intervals prior to infection. To assess the immuno-
genicity of the vaccines, SIV-specific CD8+ and memory T cell
response were analyzed by ELISPOT and lymphoproliferation
(LPR) assays, respectively, in monkeys immunized prior to
infection (Fig. 2).
SIV gag and tat-specific LPR were measured by stimulat-
ing with recombinant SIV p28 and purified viral SIV tat
protein. The gag/tat/multi-epitope and gag/tat vaccines in-
duced comparable LPR in Mamu-A*01-positive (Fig. 2A)
and -negative macaques (Fig. 2B), respectively. SIV-specific
CD8+ T cell responses were measured by depleting PBMC of
the CD4+ T cell subset prior to ELISPOT analysis. In Mamu-A*01-positive macaques, CD8+ T cell responses were mea-
sured against 8 representative CTL epitopes included in the
multi-epitope vaccine using specific peptides for stimulation.
In Mamu-A*01-negative macaques, CD8+ T cell responses
were measured against overlapping peptide pools from SIV
Gag and Tat. Both DNA vaccines induced significant levels
of SIV-specific CD8+ T cells (Figs. 2C and D). Immunization
of Mamu-A*01-positive macaques with the gag/tat/multi-epi-
tope vaccine induced significant CD8+ T cell responses to
multiple epitopes in all 8 macaques, and strong responses
against the immunodominant Gag_CM9 and Tat_SL8 epi-
topes (Allen et al., 2001) (Fig. 2C). Immunization of
Mamu-A*01-negative macaques with the SIV gag/tat vaccine
induced predominantly a Tat-specific CD8+ T cell response
(Fig. 2D). Maximum CD8+ T cell responses were similar in
both vaccine groups, but the gag/tat/multi-epitope vaccine
appeared to provide more consistent induction of CD8+ T
cell responses among all 8 animals. Among the animals
immunized with the gag/tat DNA vaccine, 3 macaques
(M11999, M12299, M12599) showed CD8+ T cell responses
that were at or below the positive threshold (25 SFC/106
PBMC) for this assay. However, these same 3 animals exhib-
ited significant proliferative responses against whole Gag and
Tat proteins (Fig. 2B) indicating that the gag/tat DNA vac-
cine effectively primed for an immune response in each
Fig. 2. SIV-specific T cell responses in vaccine-primed rhesus macaques following 4 pre-infection DNA immunizations. (A) Lymphoproliferative responses in Mamu-
A*01-positive monkeys immunized with the SIVgag/tat/multi-epitope DNA vaccine (Group A). (B) Lymphoproliferative responses in Mamu-A*01-negative
macaques immunized with the SIVgag/tat DNA vaccine (Group B). (C) CD8+ T cell responses in Mamu-A*01-positive macaques primed with the SIV gag/tat/
multi-epitopes DNA vaccine (Group A). (D) CD8+ T cell responses in Mamu-A*01-negative macaques primed with SIV gag/tat DNA vaccine (Group B). CD8+ T
cell responses were measured by ELISPOT and data shown are net values after background subtraction. In all cases, background levels were less than 25 SFC/106
PBMC.
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between animals, an outcome that is not unexpected in an
outbred species such as the rhesus macaque. Together, these
data demonstrate that both DNA vaccines induced significant
levels of SIV-specific CD8+ and CD4+ T cell responses in
the monkeys that were vaccine-primed prior to infection.
SIV infection and anti-retroviral therapy
Seven weeks after the final pre-infection DNA immuniza-
tion, all animals and 4 additional untreated infection controls,
were inoculated intravenously with the primary isolate SIV/
DeltaB670 (Fig. 1). SIV/DeltaB670 is a highly pathogenic
and causes AIDS in untreated rhesus macaques with a mean
time to death of 11 months (Seman et al., 2000). This strain was
chosen because the genetic diversity between this isolate and
the SIVmac239 and SIV17E-Fr strains used to construct the DNA
vaccines, mimics the intraclade diversity observed for HIV(Amedee et al., 1995). Despite this diversity, alignment of the
CTL epitope sequences in the gag/tat/multi-epitope DNA vac-
cine to those from the dominant variant found in SIV/DeltaB670
or the closely related SIVmmH9 consensus sequence revealed
that most of the epitopes were highly conserved in the challenge
strain. Fourteen of the 19 epitopes either contained only a single
amino acid substitution or were 100% conserved (Table 1).
Monkeys were infected by intravenous inoculation because we
had previously shown that a PMED DNA vaccine provided
protection from an intrarectal challenge with this virus in nearly
60% of the vaccinated macaques (Fuller et al., 2002) and it was
imperative to establish a disseminated infection in all animals.
ART with the nucleophosphonate analog R-9-(2-phospho-
nylmethoxypropyl) adenine (PMPA) (Tsai et al., 1995) was
initiated 2 weeks after infection, administered daily during the
6 monthly therapeutic DNA immunizations, and then with-
drawn to assess the effects of vaccination on viral control (Fig.
1). We chose to use a less aggressive monotherapy than the
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treatment of HIV because a previous study employing a triple
combination of PMPA, d4T, and DDI initiated at the same
time point resulted in significant viral containment in mock-
vaccinated control animals once therapy was discontinued, a
result that precluded statistical analysis of the augmentive
effects of immunization (Hel et al., 2000). In contrast, an
earlier experiment in our laboratory demonstrated that PMPA
alone when initiated during acute infection with SIV/Del-
taB670 did not prevent viral rebound after the drug was
discontinued (data not shown). Furthermore, macaques
infected with SIV/DeltaB670 demonstrate a shortened surviv-
al time when compared to humans infected with HIV (Mellors
et al., 1996; Riddler and Mellors, 1997; Sauermann et al.,
2000; Seman et al., 2000; Staprans et al., 1999; Watson et al.,
1997), suggesting more rapid development of immune dys-
function during acute infection in the macaque model. We
therefore reasoned that initiating ART with a single drug
during acute infection would be more similar to initiating
HAART with multiple drugs in HIV-infected humans during
later stages of infection.
Control of virus burden during and after ART
Viral loads were measured during therapy and for over 1
year after discontinuation of PMPA. SIV/DeltaB670 infection
resulted in comparable peak viral loads in all groups by 2
weeks post-infection (Fig. 3). We previously showed that
DNA vaccination prior to infection suppressed acute viremia
in animals challenged intrarectally with SIV/DeltaB670 (Full-
er et al., 2002). In the present study, however, animals immu-
nized before and after infection (Groups A and B)
demonstrated similar viral loads at 2 weeks post-infection as
animals that were not vaccinated prior to infection (Groups C,
D, PMPA controls, and naive controls) (Fig. 3) suggestingFig. 3. Mean peak acute viral loads and SEM per group at 2 weeks post-
infection. Mean viral loads were determined in each vaccine and control
group and in ART responders and ART low responders that were not vaccinated
prior to infection (from Groups C–E).that prophylactic DNA immunization may be less effective in
controlling acute SIV replication following an intravenous
infection.
The effects of vaccination on viral control were examined
in terms of the ability to contain viral rebound at a level equal
to or lower than 104 viral RNA copies/ml for a period of at
least 6 months after PMPA was withdrawn. This level was
selected because it is comparable to the mean viral load
observed in a group of 3 rare long-term nonprogressors
from a separate study in our laboratory that were infected
with a lethal dose of SIV/DeltaB670 but maintained normal
CD4 T cell numbers and clinical health for over 2–5 years in
the absence of drug treatment (data not shown). Other studies
have similarly shown that durable antiretroviral or immune
suppression of SIV at a level equal to or below 104 RNA
copies/ml prevents or delays progression to AIDS in rhesus
macaques (Fuller et al., 1997b; Hel et al., 2000; Lifson et al.,
2000; Patterson et al., 2004; Silvera et al., 2000). Since the
goal of vaccine therapy is improvement in clinical health, we
reasoned that vaccine-induced containment of viremia at this
level after PMPA was withdrawn would similarly prevent or
delay disease progression.
Naive controls infected with SIV/DeltaB670 developed
viral set points ranging from 106 to 107 viral RNA copies/
ml (Fig. 4A). In the PMPA-treated animals (Fig. 4B), viral
loads ranged from undetectable levels to over 107 viral cop-
ies/ml during PMPA treatment and increased to levels that
ranged from 2.5 × 104–107 viral RNA copies/ml in 7 of the
8 mock-vaccinated controls within the first 6 months after
PMPA was removed. Among the 32 vaccinated animals, 17
(53%) contained viral loads at levels below 104 RNA copies/
ml (undetectable levels—9600 viral RNA copies/ml) for at
least 6 months after PMPA was withdrawn and 13 (41%) of
these animals continued to control plasma viremia at this
level for 13 months (the duration of the study) in the absence
of drug treatment (Figs. 4C–F).
However, PMPA treatment suppressed viral load in only
60% (24 of 40) of the animals (Figs. 4B–F, red plots). These
animals (ART responders) demonstrated a progressive 3–6
log-fold reduction in viral load during PMPA treatment that
ranged from below the limits of detection (10 copies/ml) to
5000 copies/ml by the end of the 6-month treatment period
(week 30). The remaining 16 animals responded relatively
poorly to ART (ART low responders) demonstrating, at
most, a 2-fold log reduction in viral load in response to
therapy and viral loads that were 105–107 copies/ml during
and after the PMPA treatment period (Figs. 4B–F, black plots)
and similar to that observed in the naive controls throughout
the study (Fig. 4A).
ART responders and low responders demonstrated compa-
rable viral loads at 2 weeks post-infection (Fig. 3) indicating
PMPA responsiveness was not related to the degree of viral
replication present at the time drug was initiated. There was
also no significant difference in the number of A*01-positive
(14/20) and -negative animals (11/20) that responded to
PMPA treatment indicating that ART responsiveness was not
related to the A*01 allele (P = 0.514 by Fisher's Exact Test).
Fig. 4. Virus loads in vaccinated and control groups. (A) Untreated naïve controls; (B) mock-vaccinated PMPA-treated controls; (C, D) macaques vaccinated before and
post-infection; (E, F) macaques vaccinated only post-infection. For panel B only, the open symbols indicate Mamu-A*01-negative controls and the closed symbols
indicate Mamu-A*01-positive controls. The shaded areas indicate the period of continuous PMPA treatment. The solid vertical lines indicate the 6-month post-PMPA
evaluation time point (week 54). Virus loads below the dashed line indicates viral containment at or below 104 viral RNA copies/ml, as determined by real time PCR.
Red plots: antiretroviral (ART) responders or animals exhibiting viral load suppression below 104 RNA copies/ml during PMPA therapy. Black plots: ART low
responders or animals exhibiting viral loads above 104 RNA copies/ml during PMPA therapy. The limit of sensitivity for the viral load assay is 10 viral RNA copies/ml.
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Gotch et al., 1999; Hel et al., 2000; Lederman, 2001), we
hypothesized that vaccine immunotherapy is likely to be most
effective during ART-induced suppression of viremia. We
therefore separately evaluated the effects of vaccination in
ART responders and low responders.
A comparison of ART responders and low responders in
Fig. 4 shows that viral containment post-PMPA occurred only
in the ART responders (red plots). Viral rebound was con-
trolled for at least 6 months after PMPA was withdrawn in 17
of 20 vaccinated ART responders compared to 1 of 4 ART
responders in the mock-vaccinated control group (P = 0.035
by Fisher's Exact Test). The gag/tat/multi-epitope vaccine
prevented immediate viral rebound in all 7 ART responders
immunized before and after infection (group A, Fig. 4C) and
in all 4 ART responders immunized only after infection
(group C, Fig. 4E). The gag/tat vaccine also contained viral
rebound post-PMPA in all 4 ART responders that were im-
munized both before and post-infection (group B, Fig. 4D),but appeared to be less effective when administered only post-
infection providing viral control for at least 6 months post-
PMPA in only 2 of 5 ART responders in this group (group D,
Fig. 4F).
Disease progression
To determine if vaccination influenced disease progression,
we analyzed CD4+ T cell loss in as an indication of progression
to AIDS (Fig. 5). A stable CD4+ T cell count was defined as
maintenance of CD4 counts within 80% of the baseline value, a
level that is similar to the degree of variability we have ob-
served in healthy uninfected, naive macaques (unpublished
observations). As expected, 3 of the 4 naive controls showed
progressive loss of CD4+ T cells to levels that were below 50%
of baseline values and all 3 were sacrificed within 64 weeks
post-infection due to AIDS (Fig. 5A). The 4th naive control
animal was a rapid progressor that succumbed to AIDS within
14 weeks of infection.
Fig. 5. CD4+ T cell counts. Shown are % baseline levels in (A) naïve controls; (B) mock-vaccinated PMPA controls; (C, D) macaques vaccinated before and post-
infection; (E, F) macaques vaccinated only post-infection. Red plots: ART responders; Black plots: ART low responders.
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evident in most ART low responders (Figs. 5B–F, black plots).
By the end of the study, 15 of the 16 ART low responders
demonstrated at least a 50% decline in CD4 counts, and 12 of
these animals were sacrificed before the end of the study due to
end-stage AIDS. Similarly, all 4 ART responders in the control
group (Fig. 5B, red plots) exhibited CD4+ T cell loss after
PMPA was withdrawn. CD4 counts declined to levels that
were less than 80% of baseline measurements in all 4 animals
within 3 months after PMPA was discontinued and remained
below this threshold throughout the study. One of the ART
responders (M9099) in the control group had low viral loads
throughout the study but still exhibited significant CD4 decline.
The cause for this observation at present is not clear but sug-
gests that the bulk of viral replication in this monkey may not
have been detectable in the peripheral blood.
In contrast, 15 of the 20 vaccinated ART responders main-
tained stable CD4 counts and remained clinically healthy for
over 1 year after PMPA was withdrawn without further inter-
vention (Figs. 5D–F, red plots). Four of the 5 vaccinated ARTresponders that exhibited CD4 loss were immunized with the
gag/tat vaccine (M11299, Fig. 5D; M4700, M4900, M5200,
Fig. 5F) and had all demonstrated viral rebound after PMPA
was discontinued (see Figs. 4D and F). Late viral rebound
was also observed in 2 additional vaccinated animals between
8 and 13 months (weeks 62–84) post-PMPA (M11999, Fig.
4D and M1299, Fig. 4E), but these animals maintained stable
CD4+ T cell counts for the duration of the study (Figs. 5D
and E), suggesting that temporary vaccine-induced contain-
ment of viral load may have longer-term benefits in prevent-
ing or delaying progression of disease.
Vaccine efficacy
Since control of viremia and long-term prevention or delay of
disease progression is the goal of therapy, the effects of vacci-
nation were analyzed in the context of containment of viral
burden at or below 104 viral copies/ml plasma for a period of
at least 6 months (weeks 30–54) in addition to prevention of
CD4 decline for nearly 1 year after discontinuing ART (weeks
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because vaccination was effective only in animals that
responded to PMPA. All 4 ART responders in the control
group demonstrated viral rebound and/or CD4 decline after
PMPA was withdrawn (Table 2), whereas 15 of the 20 (75%)
vaccinated ART responders (groups A, B, C, and D) contained
viremia at or below 104 viral RNA copies for at least 6 months
and maintained CD4 counts for 1 year after PMPA was with-
drawn (P = 0.012).
Separate analysis of each vaccine group showed that 2 of
the 4 vaccine strategies provided significant therapeutic ben-
efit in ART responders when compared the controls (Table 2).
The gag/tat/multi-epitope vaccine prevented viral rebound for
at least 6 months and CD4 decline for 1 year in 6 of 7ART
responders immunized both before and after infection (group
A, P = 0.015) and all 4 ART responders immunized only
post-infection (group C, P = 0.029). The gag/tat vaccine
prevented viral rebound for at least 6 months in all 4 ART
responders immunized before and after infection, but only 3
of the 4 animals maintained stable CD4 counts for 1 year after
PMPA was withdrawn (group B, P = 0.143). The one animal
in this group that exhibited CD4 decline also showed viral
rebound 36 weeks after PMPA was withdrawn (see Fig. 4D,
M11299). The gag/tat vaccine was also less effective when
administered only after infection with only 2 of 5 animals
showing viral control and stable CD4 counts, an outcome that
was not significantly different from that observed in the
mock-vaccinated controls (group D, P = 0.444).
Animals immunized with the gag/tat/epitope vaccine (groups
A and C) demonstrated an improved virological outcome during
the first 6 months post-PMPA when compared to animals im-
munized with the gag/tat vaccine (groups B and D). All eleven
ART responders immunized with the gag/tat/multi-epitope vac-
cine (groups A and C) contained viremia for at least 6 months as
compared to 5 of 9 animals immunized with the gag/tat vaccine
(groups B and D) (P = 0.026 by Fishers exact test).
A comparison between the two immunization regimens
shows that all 11 ART responders immunized before and
after infection (groups A and B) contained viral rebound forTable 2
Effect of vaccination in ART responders: control of viremia and CD4+ T cell declin
Group: DNA vaccine Immunization
regimen
Number ART
responders
Controls Mock-vaccinated 4/8
A: gag/tat/multi-epitopes Vaccine-primed c 7/8
B: gag/tat Vaccine-primed 4/8
C: gag/tat/multi-epitopes Post-infection d 4/8
D: gag/tat Post-infection 5/8
All ART responders (Groups
A, B, C, D)
20/32
a Number of ART responders per group that controlled viremia at a level that was
discontinuing PMPA.
b Vaccine efficacy was defined as containment of viral loads for at least 6 months
withdrawn. P values were determined by comparing the outcome in each vaccinated
cases, P b 0.05 was considered significant.
c Vaccine-primed: Immunized both before and post-infection during ART.
d Post-infection: Immunized only post-infection during ART.at least 6 months after PMPA was discontinued as compared
to 6 of the 9 animals immunized only after infection (groups
C and D). This difference did not quite reach statistical
significance (P = 0.076 by Fisher's Exact Test), in part,
because of the smaller number of ART responders in the
group immunized only post-infection. However, the results
indicate an apparent trend toward vaccine-priming providing
a benefit that will need to be confirmed in further studies that
include a larger numbers of macaques per group or an ART
regimen that induces a higher responder rate.
Influence of the Mamu-A*01 MHC class I allele on vaccine
efficacy
Several studies have shown that the Mamu-A*01 allele is
associated with reduced viral load and slower disease pro-
gression in SIVmac251-infected animals (Mothe et al., 2002;
Muhl et al., 2002; Pal et al., 2002) suggesting that the
therapeutic effects of vaccination in the Mamu-A*01-positive
animals used in this study may be due to an inherent MHC-
related advantage. In this study, we observed no difference in
peak and set point virus loads (Fig. 4B) or CD4+ T cell
counts (Fig. 5B) between the 4 Mamu-A*01-positive and 4
Mamu-A*01-negative animals in the PMPA treated controls
throughout the duration of the study. This finding is not due
to the low numbers of animals in this group because similar
analysis of the larger cohort of Mamu-A*01-positive and
Mamu-A*01-negative vaccinated and unvaccinated animals
that were poor ART responders (and therefore not affected
by vaccination) also failed to reveal a significant difference
due to haplotype in viral loads (P N 0.120) or CD4+ T cell
counts (P N 0.224) (by Wilcoxon rank sum test at each time
point, data not shown). Taken together, these results provide
evidence that the Mamu-A*01 allele is not associated with
lower viral loads or slower disease progression in SIV/Del-
taB670-infected rhesus macaques and further, that therapeutic
effects observed in the vaccinated animals in this study were
not influenced by the presence or absence of the Mamu-A*01
class I allele.e after discontinuing PMPA
VLa b 104
(6 months)
VLa b 104
(12 months)
Stable CD4+ T cell
count (12 months)
Efficacy b
1/4 1/4 0/4
7/7 6/7 6/7 P = 0.015
4/4 2/4 3/4 P = 0.143
4/4 3/4 4/4 P = 0.029
3/5 2/5 2/5 P = 0.444
18/20 13/20 15/20 P = 0.012
equal to or below 104 viral RNA copies/ml for the indicated period of time after
and maintenance of stable CD4+ T cell counts for 12 months after PMPA was
group to that of the controls in the two-sided Fisher exact probability test. In all
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An effective immunotherapeutic vaccine should enhance
and sustain virus-specific T cell responses. Lymphoproliferative
responses (LPR) against whole Gag and Tat proteins were
measured during therapy as a marker of virus-specific memory
T cell responses. SIV-specific CD8+ T cell responses were also
measured in each animal by ELISPOT following stimulation of
CD4+ T cell-depleted PBMC with overlapping peptide pools
from SIV Gag and Tat and 8 representative CTL epitopes
encoded by the gag/tat/multi-epitope vaccine. The 8 epitopes
selected for this assay were conserved in the challenge strain
(Table 1) and are frequently recognized in SIV-infected
monkeys (Allen et al., 2001). Epitope-specific CD8+ T cell
responses were also measured during the first 3 months post-
infection by tetramer staining but this method was not used for
the duration the study because we found that it was less sensi-
tive than ELISPOT for detection of responses against the less
dominant epitopes in the vaccine (data not shown).
SIV-specific T cell responses were separately measured in
ART responders and low responders. In ART responders,
comparable LPR were initially detected in both control and
vaccinated groups during acute infection (Fig. 6A). However,Fig. 6. Post-infection SIV-specific LPR and CD8+ T cell responses in ART responder
ART responders; (C) LPR in ART low responders; (D) CD8+ T cell responses in AR
(Groups A and B), Open symbols: groups immunized only post-infection (Groups C
mean response and standard error (SEM) in each group. In Panel A, the mean LPR m
higher in the vaccine group than in the control group: Group A (P = 0.047 at week 6
weeks 14–30), Group C (P = 0.047 at week 14; P b 0.030 at weeks 20, 24), Group D
(SFC) measured in ART responders at the following time points was significantly hig
12, 16; P = 0.006 at week 30; P b 0.024 at weeks 48–80), Group C (P b 0.030 at
Wilcoxon rank sum test.responses in the mock-vaccinated controls progressively de-
clined to low levels by week 30 while LPR in all 4 groups of
vaccinated ART responders continued to increase to levels
that were 3–5-fold higher than that seen in the mock-vacci-
nated controls. Among all 4 vaccine groups, there were no
significant differences in the mean LPRs measured at each
time point.
Fig. 6B shows that significant SIV-specific CD8+ T cell
responses were initially detected during acute infection in
ART responders in the PMPA-treated control group, but these
responses declined by week 28 in concert with ART-induced
viral suppression with only a modest increase at week 64. In
contrast, ART responders immunized with the SIV gag/tat/
multi-epitope vaccine developed elevated SIV-specific CD8+
T cell responses during therapy that were sustained at higher
levels than that observed in the mock-vaccinated animals for
over 1 year after PMPA was withdrawn. There were no signif-
icant differences in CD8+ T cell responses detected at any time
point between animals immunized both before and after infec-
tion (group A) or those immunized only after infection (group
C). ART responders immunized with the gag/tat vaccine before
and after infection (group B) or only after infection (group D)
exhibited no differences in CD8+ T cell responses from that ofs and low responders. (A) LPR in ART responders; (B) CD8+ T cell responses in
T low responders. Closed symbols: groups immunized before and post-infection
and D). Dashed line: Mock-vaccinated PMPA controls Each value represents the
easured in ART responders at each of the following time points was significantly
; P b 0.007 at weeks 14, 20, 24; P = 0.033 at week 30), Group B (P b 0.030 at
(P b 0.030 at weeks 20–30). In Panel B, the mean number of spot forming cells
her in the vaccine group than in the control group: Group A (P b 0.012 at weeks
weeks 24, 30 and 48–80). Differences at each time point were analyzed by the
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T cell responses increased in the group immunized before and
after infection after week 64 concurrent with late viral rebound
in two animals from this group (see Fig. 4D, M11299 and
M11999). Interestingly, ART responders immunized with either
vaccine did not demonstrate temporal boosts in the CD8+ T cell
response as a result of successive DNA dosings (Fig. 6B).
Rather, CD8+ T cell responses were maintained at higher levels
throughout the study than that observed in the ART responder
controls. This result suggests that the therapeutic immuniza-
tions may not have increased the magnitude of the virus-spe-
cific CD8+ T cell response per se, but rather, prevented decline
of the memory response.
In ART low responders, all 4 DNA vaccine strategies uni-
formly failed to boost LPR (Fig. 6C) or CD8+ T cell responses
(Fig. 6D). This result is not due to an inability of ART low
responders to respond to the vaccines or infection since ART
low responders immunized prior to infection demonstrated
significant responses to vaccination prior to infection (see Fig.
2, group A: M10299; group B: M10297, M12699, M13299,
M12299), and LPR and CD8+ T cell responses measured at 2
weeks post-infection were not significantly different between
ART responders and low responders (P N 0.482 for LPR and
P N 0.790 for CD8+ T cell responses by Wilcoxon rank-sum
test). Taken together, these results suggest that the uncontrolled
SIV replication in the ART low responders likely impaired their
T cell function and ability to respond to vaccination prior to
initiation of the therapeutic immunizations.Table 3
Epitope specificity in Mamu-A*01-positive ART responders
Time p.i. a Epitope gag/tat/multi-epitope vaccine (Pre- and post-infection)
M 10497 M 11197 M 11499 M 12899 M 12997 M
Weeks
14–18
Gag_CM9 ++++ b + + + +++ +
Gag_LA9 +
Pol_GM10 + + + +
Env_TL9 ++ + + ++
Env_ST10 + +
Env_CL9 + + +
Tat_SL8 + + +
Vif_QA9 + +
Weeks
38–54
Gag_CM9 ++++ ++ + + + ++
Gag_LA9
Pol_GM10 + + + +
Env_TL9 + + + +
Env_ST10 + + +
Env_CL9 ++++ + + +
Tat_SL8 + + + + + +
Vif_QA9 + +
Weeks
72–84
Gag_CM9 ++++ +++ ++ +++ + ++
Gag_LA9 +
Pol_GM10 + +
Env_TL9 + +
Env_ST10 + +
Env_CL9 + + + + +
Tat_SL8 +
Vif_QA9 ++++ + ++ + +
a Time post-infection.
b + = 25–99; ++ = 100–199; +++ = 200–299; ++++ N 300 SFC/106 PBMC.The influence of vaccination on the breadth of the CD8+ T
cell response was examined in Mamu-A*01-positive macaques.
The ELISPOT assay was used to measure individual responses
to each of the 19 epitopes encoded by the multi-epitope vaccine
in Mamu-A*01-positive animals at 10, 28, and 56 weeks post-
infection. Significant CD8+ T cell responses were detected in
each animal against one or more epitopes, but the repertoire
was limited to 8 CTL epitopes that were previously shown to be
the most consistently recognized in unvaccinated SIV-infected
macaques (Allen et al., 2001). Responses against the remaining
11 epitopes encoded by the vaccine were either undetectable or
detected at low levels at only one or two time points (data not
shown). These results suggest that immunization enhanced the
CD8+ T cell response against multiple epitopes but did not alter
the relative hierarchy of epitope dominance that develops dur-
ing infection.
The breadth of the CD8+ T cell response in each Mamu-
A*01-positive animal was further examined by measuring the
average response that developed against each of the 8 dominant
epitopes during the treatment period (weeks 14–18), and after
PMPAwas withdrawn (weeks 38–54 and weeks 72–84) (Table
3). The breadth of the responses differed markedly between the
different groups. In ART responder controls, the CD8+ T cell
response was limited to only 1–2 epitopes during the early
(weeks 14–18) and middle phases (weeks 38–54) of the
study and directed primarily against the immunodominant
Gag_CM9 epitope. This limited CD8+ T cell response was
also observed in both vaccinated and control ART lowgag/tat/multi-epitope vaccine
(Post-infection)
Controls
13999 M 14199 M 0498 M 1299 M 5000 M 9997 M 9099 M 13799
+ + + + ++ + +
++ +
++ + +
+ + +
+ +
+ +
+ ++
+ +
++ + ++ + + + +
+
+ + + + +
+ + +
+ +
+ + + + + +
+ +
+ ++++ + ++ + ++ ++ +
+ +
+ + + + +
+ + +
+ + + + +
++ + + + + ++++ +
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responders demonstrated a broader CD8+ T cell response dur-
ing this period that included, in addition to Gag_CM9, 3–7 less
dominant epitopes. Differences in the breadth of the CD8+ T
cell response during acute infection (weeks 14–18) were also
evident in ART responders that were vaccine-primed with the
gag/tat/multi-epitope vaccine (Group A) when compared to
those immunized with the same vaccine only post-infection
(Group C). All 7 vaccine-primed ART responders developed
multi-specific CD8+ T cell responses against 3–7 epitopes
while 2 of the 4 ART responders immunized only post-infection
demonstrated a more limited response against only a single
epitope during this period (Table 3, weeks 14–18). This result
is consistent with previous studies showing that DNA immuni-
zation before infection can increase the breadth of the SIV-
specific CD8+ T cell responses during acute infection (Barouch
et al., 2001; Radaelli et al., 2003). During the post-PMPA
phases (weeks 38–52 and 72–84), the breadth of the CD8+ T
cell response in all 4 ART responders immunized only after
infection expanded to 3–8 epitopes and was comparable to that
seen in the vaccine-primed animals, indicating that immuniza-
tion with the gag/tat/multi-epitope DNA vaccine after infection
was established may have altered the existing repertoire of
virus-specific CD8+ T cell responses.
Discussion
This study demonstrates for the first time that DNA immu-
nization when administered as an adjunct to transient antiretro-
viral therapy either before and post-infection or only post-
infection can induce durable immune control of a virulent,
primary AIDS virus after drug is withdrawn. Further, this effect
was associated with vaccine-induced T cell responses that were
both greater in magnitude and broader in epitope specificity
than that induced by viral infection alone.
However, the efficacy of therapeutic DNA vaccination was
dependent on the virologic response to ART because contain-
ment of viral rebound was observed only in vaccinated animals
that responded to PMPA. This observation is similar to a previ-
ous study where enhancement of virus-specific T cell responses
in SIV-infected macaques by a recombinant poxvirus vaccine
was dependent on suppression of viremia by a more potent triple
drug regimen (Hel et al., 2000). In that study, however, signifi-
cant viral containment was also observed in the mock-vaccinat-
ed control animals after HAARTwas discontinued, an outcome
that compromised evaluation of the effects of vaccination on
viral control. A more recent study demonstrated reduction in
virus loads following therapeutic poxvirus immunizations in
chronically-infected macaques, but this effect was transient
(Tryniszewska et al., 2002). The results reported here represent
an important advance from these earlier findings because DNA
vaccination induced persistent control of viral burden in the
majority of ART responders for over 1 year after discontinuing
drug therapy (e.g., the full duration of the study). Moreover,
these effects were achieved in combination with a less rigorous
ART regimen employing only a single drug and in a setting
where virus burden remained above the threshold of detection.The observation that ART low responders failed to respond
to DNA immunization even though the vaccine was adminis-
tered only 56 days post-infection suggests that considerable
immune impairment had already taken place in these animals
during acute infection. At least partial preservation of immune
function would be expected in ART responders (Autran et al.,
1999; Lederman, 2001; Valdez, 2002). It is therefore not sur-
prising that these animals were better able to respond to vacci-
nation. This observation suggests that in a setting where
infection is associated with a naturally lower viral set point
and slower impairment of immune function, HAART may not
be required for effective immunotherapy. A previous study
employing antigen-loaded autologous dendritic cells as a ther-
apeutic vaccine demonstrated significant virus load reduction in
Chinese origin rhesus macaques without the need for HAART
(Lu et al., 2003). Since SIV infection of this subspecies is
associated with a 2–3 log lower viral load and slower disease
progression than the Indian origin rhesus macaques used in our
study, a more competent T cell response is likely retained in
Chinese origin macaques in the absence of additional drug-
induced virus suppression (Ling et al., 2002a, 2002b; Marthas
et al., 2001; Trichel et al., 2002). Together, these results suggest
that the outcome of therapeutic immunization may not depend
on the response to ART per se, but rather the relative compe-
tence of the immune system to respond to antigen stimulation
when therapy is introduced.
Macaques immunized with CTL epitopes in addition to gag
and tat developed a higher and broader repertoire of CD8+ T
cell responses, but comparable levels of SIV-specific LPR,
when compared to macaques immunized only with the gag/tat
DNA vaccine. Interestingly, only the gag/tat/multi-epitope vac-
cine was effective when administered only post-infection. This
result supports the concept that increasing the magnitude and/or
breadth of the virus-specific CD8+ T cell response after an
infection has been established can improve viral control and
clinical outcome. This result further suggests that therapeutic
immunization with an epitope-based DNA vaccine is an effec-
tive strategy to achieve this goal.
We found no evidence that the Mamu-A*01 allele provides a
protective effect on viral load or CD4+ T cell loss in animals
infected intravenously with SIV/DeltaB670. This result strong-
ly indicates that the improved outcome observed in the Mamu-
A*01-positive animals was due to the effects of the gag/tat/
multi-epitope vaccine and not genetic background. Our find-
ings that the Mamu-A*01 allele does not influence viremia or
disease progression in SIV/DeltaB670-infected macaques are in
contrast with several studies reporting a significant Mamu-
A*01-related protective effect on viral load and disease pro-
gression in macaques infected with SIVmac251 (Mothe et al.,
2003; Muhl et al., 2002; Pal et al., 2002). This suggests that the
influence of genetic background on SIV infection may depend
on the viral stock employed. Consistent with this possibility,
Pal et al. (2002) also did not observe a Mamu-A*01-related
protective effect on viremia in rhesus macaques infected with
the closely related SIVSME660 viral stock, although in that study,
CD4+ T cell counts were found to be higher in the Mamu-
A*01-positive animals.
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viral load following intravenous challenge. This result is in
contrast to a previous finding in our laboratory where 4 of 7
animals immunized with 7 doses of a particle-mediated DNA
vaccine encoding SIV gag/pol/env were protected from intrar-
ectal challenge with the same viral strain (Fuller et al., 2002).
Particle-mediated epidermal DNA immunization induces mu-
cosal immune responses in the gut associated lymphoid tissue
(GALT) (Chen et al., 2001; Fuller et al., 2002) and the
different outcomes in these two studies may be due to the
induction of mucosal immune responses that can provide an
additive protective barrier against intrarectal but not intrave-
nous exposure to the virus. Furthermore, in the previous
study, the 3 animals that were not protected developed plas-
ma viral loads that were indistinguishable from the controls,
suggesting that the peripheral blood immune responses were
less effective in controlling the virus once it penetrated the
mucosal barrier. Consistent with this possibility, a previous
study showed that animals that developed class I restricted
CTL responses in the GALT as a result of rectal exposure to
a low dose of replication competent virus had sterilizing
protection against a high-dose rectal challenge with SIV
while those with undetectable responses in the GALT dem-
onstrated plasma viral loads that were similar to that of the
controls (Murphey-Corb et al., 1999). Although differences in
the number of doses and/or composition of the two vaccines
cannot be ruled out as a cause for the different outcomes of
the two studies, these data suggest that particle-mediated
DNA immunization may afford better mucosal than systemic
protection against SIV.
Our data indicate that immunizing prior to infection
enhances the effects of post-infection vaccine immunotherapy.
Since our study did not include a group immunized only before
infection, we cannot exclude the possibility that vaccination
prior to infection and PMPA therapy alone could be sufficient
to provide this benefit. However, immunization only post-in-
fection with the SIV gag/tat/epitope provided a therapeutic
benefit in ART responders, providing strong evidence that the
DNA immunizations administered post-infection provided ad-
ditional benefit in animals that were immunized both before
and post-infection. Interestingly, the gag/tat vaccine induced
strong LPR but only modest CD8+ T cell responses. Neverthe-
less, immunizing with this vaccine both before and after infec-
tion prevented viral rebound for at least 6 months in all 4 ART
responders. This result suggests that less potent vaccines may
still provide some benefit if administered both before and after
infection. This observation may prove important in ongoing
and future prophylactic vaccine trials in humans where candi-
date vaccines may nevertheless fail to prevent the establishment
of infection (Letvin et al., 2002). Vaccinated, infected indivi-
duals from these trials may be excellent candidates for subse-
quent immunizations post-infection, perhaps even in the
absence of HAART. Such an approach may be particularly
useful in developing countries where widespread use of costly
drug regimens may not be possible.
In summary, an effective therapeutic vaccine should ideally
replenish virus-specific CD4+ T cells and maintain or boostvirus-specific CD8+ T cell responses. Our studies are consistent
with this hypothesis and further indicate that these vaccines
should induce responses against a broad repertoire of CTL
epitopes. The ability of these DNAvaccine strategies to provide
a significant therapeutic benefit in the rigorous model system
employed in these studies provides compelling evidence that
DNA immunization is a promising approach for treating HIV
infection in humans and reducing long-term dependence on
complex drug regimens. What remains now is the development
of strategies that provide similar benefits in those individuals
that respond poorly to antiretroviral drugs.
Materials and methods
Rhesus macaques
Macaques were maintained in accordance with the NIH
Guide to the Care and Use of Laboratory Animals under the
approval of the University of Pittsburgh Institutional Animal
Care and Use review committee. The University of Pittsburgh
is accredited by the American Association for the Accreditation
of Laboratory Animal Care International. Rhesus macaques
were identified as Mamu-A*01 positive by PCR-SSP and by
direct sequencing as previously described (Knapp et al., 1997).
HBcAg-multi-epitope DNA vaccine
The hepatitis B core antigen (HBcAg) carrier expression
vector PJV7198 (PowderJect Vaccines, Inc., Middleton, WI)
expresses a modified HBcAg under the control of the CMV
immediate early promoter. It contains a unique Bsp120I restric-
tion site within the immunodominant loop of HBcAg between
amino acids 80 and 81, and a unique Not I restriction site at the
C-terminus, facilitating insertion of epitope sequences at either
site (Lesinski et al., 2001). To construct chimeric HBcAg-
epitope DNA vaccines, PJV7198 was digested with either
Bsp120I or NotI (New England Biolabs, Beverly, MA). Oligo-
nucleotides encoding codon-optimized SIV CTL epitopes and
flanked by Bsp120I or NotI were synthesized, annealed, and
ligated into PJV7198 at either the immunodominant or C-ter-
minus regions of the HBcAg gene. A total of Twenty-one SIV-
specific CTL epitopes (Allen et al., 2001) (Table 1) were
inserted into 9 HBc-epitope plasmids. Each plasmid contains
1–3 epitopes separated by 2 alanines that were inserted into
either the internal or C-terminus region of the HBcAg gene as
follows:Plasmid CTL epitopes Insert position1. pHBc-SIV-CM9 Gag_CM9 Internal
2. pHBc-SIV-SL8 Tat_SL8 Internal
3. pHBc-SIV-SI9 Env_SI9 C-terminus
4. pHBc-SIV-A Vif_QA9, Pol_LV10, Env_ST10 C-terminus
5. pHBc-SIV-B Env_CL9, Pol_YI9, Pol_EA11 C-terminus
6. pHBc-SIV-C Gag_VT10, Pol_SV9 Internal
7. pHBc-SIV-D Pol_GF10, Vif_VI8, Tat_TL8 Internal
8. pHBc-SIV-E Pol_IL-10, Env_TL9, Pol_MI8 C-terminus
9. pHBc-SIV-F Pol_QV9, Gag_LA9, Pol_GM10 C-terminus
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The SIV gag/tat DNA vaccine is a cocktail of two plasmids,
pcSIVgag and pcSIVtat (PJV 7271) (PowderJect Vaccines, Inc.
Madison, WI), that encode the full-length SIVmac239 p55 gag
and tat genes under the control of the CMV immediate early
promoter. Both plasmids were constructed and tested for in
vitro expression of their respective antigens and in vivo immu-
nogenicity as previously described (Vogel et al., 2003).
DNA immunizations
Plasmid DNA was precipitated onto 1–3 μm gold particles
as previously described (Roy et al., 2000) at a rate of 2.0 μg
DNA per 1.0 mg of gold. Each of the 9 HBc-SIV epitope
plasmids and the SIV gag and tat DNA vaccines were coated
onto separate gold particles and then mixed prior to adminis-
tration. Animals were sedated with ketamine (Parke-Davis,
Ann Arbor, MI) (10 mg/kg), the abdominal and inner leg fur
was clipped,, and DNA-coated gold particles were accelerated
into the skin of both the abdominal and inguinal lymph node
regions using the PowderJect® XR1 gene delivery device
(PowderJect Vaccines, Inc., Middleton, WI) to deliver the
DNA directly into the cells of the epidermis. DNA/gold was
delivered at a helium pressure of 500–600 pounds per square
in. Each delivery consisted of 1.0 mg of gold and 2.0 μg of
DNA. A dose of 32 μg of total DNA per immunization was
achieved by administering the DNA vaccines into 16 sites.
DNA immunizations administered prior to infection were
spaced 6–8 weeks apart, and post-infection therapeutic vacci-
nations were spaced 4 weeks apart.
Viral challenge
Macaques were fasted for 12 h, sedated with ketamine and
challenged intravenously with 1 ml of RPMI containing 100
TCID50 of cryopreserved SIV/DeltaB670. Clinical status was
monitored by complete blood cell counts and physical exami-
nation that consisted of palpating peripheral lymph nodes and
spleen and monitoring for signs of opportunistic infections.
CD4+ T cell counts were measured by flow cytometry on
fresh or frozen PBMC as described (Martin et al., 1993).
Anti-retroviral therapy (ART)
Rhesus macaques received daily subcutaneous injections of
the anti-retroviral (R]-9-[2-phosphonylmethoxypropyl]ade-
nine) (PMPA) (Gilead Biosciences, Foster City, CA) at a dos-
age of 20 mg/kg starting 2 weeks after infection. ART was
continued without interruption for 28 weeks and then discon-
tinued to monitor the effects of vaccination on viral rebound
and progression to disease.
Plasma viral loads
Virion-associated RNA in plasma was quantified by real-
time PCR in a Prism 7700 (Applied Biosystems, Inc., FosterCity, CA) using primers specific for the viral long terminal
repeat as described (Fuller et al., 2002). This assay has a
sensitivity threshold of 10 copies/reaction and is linear over
an 8-log range of template copy number. Control amplifications
of samples omitting reverse transcriptase yielded negative
results. RNA copy numbers from the unknown plasma samples
were calculated from a similarly amplified external standard
and expressed as RNA copies/ml plasma.
Proliferation assay
Rhesus macaque PBMCs were isolated by Ficoll density
gradient centrifugation and washed 3 times with RPMI 1640
(Life Technologies, Gibco BRL) supplemented with Human
AB+ serum (BioWhittaker, Walkersville, MD) (R10AB).
PBMC (200,000/well) were aliquoted into 96-well flat-bot-
tomed plates in triplicates in 100 μl R10AB. SIV Gag p28
recombinant protein (Trinity Biosciences, Frederick, MD) and
purified SIV Tat viral protein were added at 0.2 μg/well in 100
μl R10AB. Medium containing no antigen was added to neg-
ative control wells and 5 μg/ml Conconavalin A (Sigma, St.
Louis, MO) was added to positive control wells. Plates were
incubated for 6 days before adding 1 μCi tritiated thymidine to
each well. After a 16- to 18-h incubation in the presence of
radionucleotide, cells were harvested onto 96-well Unifilter GC
plates (Packard Bioscience, Meridien, CT) and counted on a
Topcount scintillation counter (Packard Bioscience). Counts
per minute (CPM) were averaged for triplicate wells and stim-
ulation indices were calculated by dividing the average CPM
obtained from test wells by the average CPM from the negative
control wells.
IFN-γ ELISPOT assay
SIV-specific CD8+ T cells secreting IFN-γ were enumerated
using the previously described ELISPOT protocol (Roy et al.,
2000) modified for the macaque system. PVDF filter 96-well
plates (Millipore, Bedford, MA) were coated with 10 μg/well of
anti-IFN-γ mAb MD-1 (U-Cytech-BV, The Netherlands) over-
night at 4 °C. The plates were then washed 4 times with sterile
PBS (BioWhittaker) and blocked with RPMI-10% fetal calf
serum for 1 h at 37 °C. Blocking solution was discarded and
10 μM synthetic peptide (QCB, Hopkinton, MA) and/or Gag
and Tat pepsets (Chiron, Emeryville, CA) consisting of 15-mer
peptides overlapping by 11 amino acids were added to each
well. 5 μg/ml Concanavalin A was added to positive control
wells and 10 μM of an irrelevant peptide or no peptide was
added to negative control wells. PBMC were isolated from
heparinized blood by Ficoll gradient (Histopaque-1077,
Sigma) and CD4+ T cells were depleted with antibody-coated
magnetic beads (Dynal, Oslo, Norway). CD4+ T cell-depleted
PBMC were added at a rate of to 4 × 105 or 2 × 105 each well.
Following 24–48 h incubation at 37 °C, 5% CO2, the cells were
removed and 200 μl/well of deionized water was added to lyse
the remaining PBMC. The plates were then washed 4 times
with PBS, and 1 μg/well of rabbit anti-IFNγ polyclonal bioti-
nylated detector antibody (U-Cytech-BV) added. After 2 h at
213D.H. Fuller et al. / Virology 348 (2006) 200–215room temperature or overnight at 4 °C, the plates were washed
5 times, incubated for 1 h with 50 μl/well of 1:1000 solution of
streptavidin–alkaline phosphatase (BioRad, Hercules, CA),
washed 5×, and 50 μl of BCIP/NTP membrane substrate
(BioRad) was added to develop spots. Spot forming cells
(SFC) were enumerated with ImagePro Plus software (Media
Cybernetics, Silver Spring, MD). Responses significantly
higher than background levels (twice the SFCs from untreated
PBMC plus 10 spots) were considered positive.
Prior to ELISPOT analysis, the effectiveness of the CD4+ T
cell depletion was measured in 3 representative animals by flow
cytometry. Following depletion, cells in the isolated subset
were stained in the dark in 100 μl FACS buffer with 10 μl
anti-rhesus CD3 FITC and 10 μl anti-rhesus CD4 APC conju-
gated antibodies (Becton Dickinson Biosciences, San Jose, CA)
for 30 min at room temperature. The cells were then washed
with FACS-buffer and fixed with 450 μl of 2% paraformalde-
hyde. Data were acquired on a Becton Dickinson FACSCalibur
instrument and analyzed using CellQuest software (Becton
Dickinson Immunocytometry Systems, San Jose, CA). In all 3
samples, staining of CD4+ T cells following the depletion was
less than 0.02% (data not shown).
Statistical analysis
Data from the vaccinated and control groups were compared
by the Wilcoxon rank sum test at each time point. Vaccine
efficacy was analyzed by the Fisher exact probability test. All
P values reported are two-sided. In all cases, P b 0.05 was
considered significant. Except where noted, the statistical anal-
ysis used to determine each indicated P value is described in the
corresponding figure legend or table.Acknowledgments
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